Century Therapeutics (NASDAQ:IPSC – Get Free Report) had its target price cut by stock analysts at Piper Sandler from $12.00 ...

Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the develo ...

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target ...

Working with a plug-and-play platform that can be applied to multiple therapeutic targets, Cytovia is advancing universal iPSC NK cells and iPSC CAR NK cells. A non-engineered universal candidate ...

Piper Sandler lowered the firm’s price target on Century Therapeutics (IPSC) to $4 from $12 and keeps an Overweight rating on the shares.

and actually reach its target; a key consideration with neuroscience therapies as direct access to the brain is blocked by the blood brain barrier. The complex, co-culture models and human iPSC ...

The increasing implication of glial cells in neurodegenerative diseases makes them an appealing addition to iPSC-based model systems for investigating ... has allowed Dr. Fossati’s lab to identify and ...

Clinical grade iPSC lines that are capable of generating high yields of immune cells are genetically engineered using the CRISPR/MAD7 system to target cancer cells, avoid rejection by the host ...